Hyperactivity News and Research

RSS

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

Malfunctioning circadian clock genes may be associated with bipolar disorder in children

Malfunctioning circadian clock genes may be responsible for bipolar disorder in children. Researchers writing in the open access journal BMC Psychiatry found four versions of the regulatory gene RORB that were associated with pediatric bipolar disorder.

11 Nov 2009

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.

11 Nov 2009

Shire's INTUNIV for treating ADHD now available in the U.S.

Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.

9 Nov 2009

"Doctor's Orders" to explore trends in health and medicine

The partnership between ABC News and MedPage Today entered a new phase with the November 1 premiere of "Doctor's Orders," a featured series on Good Morning America Weekend.

6 Nov 2009

Surgery may not be the best option for children with obstructive sleep apnea

For children with obstructive sleep apnea, standard care often includes a tonsillectomy and adenoidectomy. But researchers at Saint Louis University say further research is needed to determine if surgery is the best option for these patients.

5 Nov 2009

Medidata Solutions announces multi-year contract extension with Shire

Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced a multi-year contract extension with Shire plc for use of Medidata Grants Manager™ and CRO Contractor™ benchmarking and analysis tools for investigator site and contract research organization (CRO) trial budget planning and forecasting.

4 Nov 2009

Marianjoy Rehabilitation Hospital offers behavioral testing for children

Marianjoy Rehabilitation Hospital now provides neuropsychological assessments and testing for children ages 5 to 18 who are exhibiting behavioral issues or academic difficulties.

4 Nov 2009

Cost of ADHD clinical trials can be reduced by implementing Quotient ADHD System

BioBehavioral Diagnostics Company announced today that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009.

4 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

New study results of INTUNIV presented at a major psychiatric medical meeting

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today.

31 Oct 2009

Shire announces third quarter 2009 financial results

Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

31 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

Study links low maternal folate levels with attention-deficit/hyperactivity problems in children

It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.

29 Oct 2009

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

InfoMedics, Inc., a company that engages patients and physicians to communicate better through the delivery of treatment feedback, has poster presentations at three industry conferences in October 2009. All of these studies provide a unique look at real-life patient feedback regarding experiences with medications for chronic conditions including ulcerative colitis (UC) and attention-deficit/hyperactivity disorder (ADHD) in adults and children.

28 Oct 2009

Hyperactivity News and Research

Shire announces findings from Phase 3 study data with Vyvanse

Malfunctioning circadian clock genes may be associated with bipolar disorder in children

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Shire's INTUNIV for treating ADHD now available in the U.S.

"Doctor's Orders" to explore trends in health and medicine

Surgery may not be the best option for children with obstructive sleep apnea

Medidata Solutions announces multi-year contract extension with Shire

Marianjoy Rehabilitation Hospital offers behavioral testing for children

Cost of ADHD clinical trials can be reduced by implementing Quotient ADHD System

Phase 1 study of STX107 for Fragile X syndrome begins

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire announces Phase IIIb study results of Daytrana

New study results of INTUNIV presented at a major psychiatric medical meeting

Shire announces third quarter 2009 financial results

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Study links low maternal folate levels with attention-deficit/hyperactivity problems in children

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

Two-year trial to test effectiveness of behavioral psychotherapy for young adolescents with autism

New therapy for decreasing anxiety and improving psychological well-being in children

Deep brain stimulation: New treatment option for people with severe Tourette syndrome

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News